QPMind is a new kind of biotech company – the first biotech company to apply the combination of AI with Quantitative Systems Pharmacology (QSP), a sophisticated method of biological modeling, to drive the drug discovery process de novo with a platform approach for central nervous system (CNS) diseases. The company was founded in 2023 by experienced entrepreneurs in biotech who know drug discovery, AI for drug discovery and QSP modeling, and who have significant prior work to draw upon for QPMind’s initial platform.
Focusing on CNS diseases, QPMInd is beginning with two drug candidates for Alzheimer’s Disease, and for several neurodegenerative orphan indications involving tauopathy. QPMind has a partnership with Sanford Burnham on these initial drugs. The company further has discovery stage programs in pain management, Schizophrenia and Parkinson’s Disease.
QPMind’s vision is to build an organically growing QSP model base that can be applied to all aspects of drug discovery and development to reduce the cost and increase the success rate of drugs in the clinic by a factor of five. The growing model base combined with AI and experts in the field acts as a “super mind” for drug discovery, delivering an efficiency like no prior approach.
QPMind is organized as an LLC holding company of drug assets. Each drug development asset is contained in a separate C-corporation subsidiary to enable direct investment, risk sharing or partner collaboration directly into specific programs, as well as tax advantaged exits. The platform which services all of the drug development programs is also contained in a C-corp subsidiary.